Shareholder Notice: Robbins LLP Informs Investors of the ARS Pharmaceuticals Inc. Class Action
Robbins LLP informs shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class Period"). ARS is a clinical stage biopharmaceutical company focused on the development and commercialization of neffy for needle-free intranasal delivery of epinephrine for emergency treatment of Type 1 allergic reactions, including anaphylaxis.
Investors who suffered losses during the Class Period may have legal rights. If you want to seek appointment as lead plaintiff, contact Robbins LLP.
Why Was ARS Pharmaceuticals Sued?
According to the complaint, defendants provided investors with material information concerning ARS's expected timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. Defendants’ statements included, among other things, confidence that this coverage would begin on July 1, 2026, and be in place for the summer and back-to-school allergy seasons. Plaintiff contends that defendants provided these overwhelmingly positive statements to investors while, at the same time, failing to adequately disclose the risk that the expanded insurance coverage may not be available by the July 1 deadline, and thus, ARS would not have the expanded insurance coverage for neffy with CVS Caremark for the summer and back-to-school seasons.
